Express Healthcare
Home  »  News  »  ICMR study finds Covaxin effective against COVID-19 Delta Plus variant

ICMR study finds Covaxin effective against COVID-19 Delta Plus variant

0 80
Read Article

Covaxin showed a 65.2 per cent protection against the Delta variant in a double-blind, randomised, multi-centre, phase-III clinical trial

Bharat Biotech’s COVID-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in biorxiv by the Indian Council of Medical and Research (ICMR).

“Here, we have evaluated the IgG antibody titer and neutralising potential of sera of COVID-19 naive individuals full doses of BBV152 vaccine, COVID-19 recovered cases with full dose vaccines and breakthrough cases post-immunisation BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.,” the study said.

The recent emergence of the SARS-CoV-2 Variant B.1.617.2 (Delta) variant with its high transmissibility has led to the second wave in India. Covaxin showed a 65.2 per cent protection against the Delta variant in a double-blind, randomised, multi-centre, phase-III clinical trial.

Subsequently, Delta has further mutated to Delta AY.1, AY.2, and AY.3. Of these, AY.1 variant was first detected in India in April 2021 and subsequently from 20 other countries as well, the study said.

The study is a pre-print and has not been peer-reviewed. Covaxin demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the B.1.617.2 Delta variant, Bharat Biotech had said while concluding the final analysis of Covaxin efficacy from phase-III trials on July 3.

Edited by EH Bureau

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image
The Radiology Conclave : Embrace the new normal
Register Now
close-image